Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;33(11):2899-2914.
doi: 10.1007/s11136-024-03734-9. Epub 2024 Aug 22.

A systematic review of health state utility values for older people with acute myeloid leukaemia

Elise Button  1 , Hannah Carter  2 , Nicole C Gavin  3 , Thomas W LeBlanc  4 , Nikki McCaffrey  5
Affiliations

A systematic review of health state utility values for older people with acute myeloid leukaemia

Elise Button et al. Qual Life Res. 2024 Nov.

Abstract

Purpose: Older people with acute myeloid leukaemia (AML) have a poor prognosis, reduced health-related quality of life (HRQoL) and require substantial healthcare resources. The objectives of this systematic review were to determine what health state utility values (HSUVs) are reported in the literature that can be used in economic evaluations of interventions for older people with AML, identify research gaps, and discuss directions for future research.

Methods: The following databases were searched for studies published from inception until Feb 2023: PubMed, EMBASE, CINAHL, PsycINFO, Cochrane, and EconLit. Studies were included if they reported on HSUVs of people with AML >60 years, or HRQoL data that could be mapped to HSUVs using currently published algorithms.

Results: Of 532 studies identified, 7 met inclusion (4 full studies and 3 conference abstracts). Twenty-eight potentially eligible studies were excluded as they did not report HRQoL measures in sufficient detail to be mapped to utility values. Included studies reported on health states of newly diagnosed disease (n=4 studies), intensive therapy (n=1 study), controlled remission (n=3 studies), and relapsed or refractory disease (n=2 studies). No studies reported on low intensity therapy or supportive care health states. Utility values were largely reported via the EuroQol and ranged from 0.535 (intensive therapy) to 0.834 (controlled remission).

Conclusion: There are gaps in knowledge on HSUVs for older people with AML, particularly for certain treatment-related health states. Future articles should publish comprehensive HRQoL outcomes to enable use in economic evaluation.

Keywords: Quality of life; Acute myeloid leukaemia; Health state utility value; Older person.

PubMed Disclaimer

Conflict of interest statement

Elise Button, Nikki McCaffrey, Hannah Carter, and Nicole Gavin declare they have no financial interests. Thomas LeBlanc has the following declarations: (i) currently, or has recently been a consultant for/received honoraria from AbbVie, Agilix, Agios/Servier, Astellas, AstraZeneca, Beigene, BlueNote, BMS/Celgene, CareVive, Flatiron, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer; (ii) served on recent advisory boards for AbbVie, Agios, and BMS; ii) has received honoraria from AbbVie, Agios, Astellas, BMS/Celgene, and Incyte for recent speaking engagements; iv) has equity interest in Dosentrx; v) and has received recent research funding from the AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society, the National Institute of Nursing Research/ National Institutes of Health, and Seattle Genetics.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram
See this image and copyright information in PMC

References

    1. Leaukaemia Foundation. (2020). Acute myeloid leukaemia [cited 2022 5th Feb]; https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-can....
    1. Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, CA, 2019. CA: A Cancer Journal for Clinicians, 69(1), 7–34. - PubMed
    1. Fitzmaurice, C., et al. (2018). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncology, 4(11), 1553–1568. - PMC - PubMed
    1. Yi, M., et al. (2020). The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: Estimates based on the global burden of disease study 2017. Journal of Hematology & Oncology, 13(1), 1–16. - PMC - PubMed
    1. Abdallah, M., et al. (2020). Management of acute myeloid leukemia (AML) in older patients. Current Oncology Reports, 22(10), 1–14. - PMC - PubMed

Publication types

LinkOut - more resources